Skip to content

Study · Animal study (in vivo) · mouse · 2009

7 results

Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease.

Martin B, Golden E, Carlson OD, Pistell P, Zhou J, Kim W, Frank BP, Thomas S, Chadwick WA, Greig NH, Bates GP, Sathasivam K and 4 more

Show all authors

Bernier M, Maudsley S, Mattson MP, Egan JM

Diabetes4 Nov 2008Cited by 146 (Europe PMC)

PMID18984744 (opens in a new tab)DOI10.2337/db08-0799 (opens in a new tab)PepBankPUB-18984744
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Huntington's disease mice, exendin‑4 ameliorated abnormalities in peripheral glucose regulation.

    In plain wordsIn mice with Huntington's disease, exendin‑4 improved abnormal blood glucose regulation.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedPeripheral glucose regulation
    Study

    mousen: not reported in source

    Huntington's disease mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Ex-4 treatment ameliorated abnormalities in peripheral glucose regulation and suppressed cellular pathology in both brain and pancreas in a mouse model of Huntington's disease.
    2 context sentences
    Summary · context
    Huntington's disease mice were treated with an FDA-approved antidiabetic glucagon-like peptide 1 receptor agonist, exendin-4 (Ex-4), to test whether euglycemia could be achieved, whether pancreatic dysfunction could be alleviated, and whether the mice showed any neurological benefit.
    Summary · context
    Additionally, motor performance and life span were quantified and mutant huntingtin (mhtt) aggregates were measured in both the pancreas and brain.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In Huntington's disease mice, exendin‑4 suppressed brain cellular pathology.

    In plain wordsIn mice with Huntington's disease, exendin‑4 reduced cellular damage in the brain.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBrain cellular pathology
    Study

    mousen: not reported in source

    Huntington's disease mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Ex-4 treatment ameliorated abnormalities in peripheral glucose regulation and suppressed cellular pathology in both brain and pancreas in a mouse model of Huntington's disease.
    2 context sentences
    Summary · context
    Huntington's disease mice were treated with an FDA-approved antidiabetic glucagon-like peptide 1 receptor agonist, exendin-4 (Ex-4), to test whether euglycemia could be achieved, whether pancreatic dysfunction could be alleviated, and whether the mice showed any neurological benefit.
    Summary · context
    Additionally, motor performance and life span were quantified and mutant huntingtin (mhtt) aggregates were measured in both the pancreas and brain.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In Huntington's disease mice, exendin‑4 suppressed pancreatic cellular pathology.

    In plain wordsIn mice with Huntington's disease, exendin‑4 reduced cellular damage in the pancreas.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePancreatic cellular pathology
    Study

    mousen: not reported in source

    Huntington's disease mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Ex-4 treatment ameliorated abnormalities in peripheral glucose regulation and suppressed cellular pathology in both brain and pancreas in a mouse model of Huntington's disease.
    2 context sentences
    Summary · context
    Huntington's disease mice were treated with an FDA-approved antidiabetic glucagon-like peptide 1 receptor agonist, exendin-4 (Ex-4), to test whether euglycemia could be achieved, whether pancreatic dysfunction could be alleviated, and whether the mice showed any neurological benefit.
    Summary · context
    Additionally, motor performance and life span were quantified and mutant huntingtin (mhtt) aggregates were measured in both the pancreas and brain.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In Huntington's disease mice, exendin‑4 improved motor function.

    In plain wordsIn mice with Huntington's disease, exendin‑4 improved movement.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseMotor function
    Study

    mousen: not reported in source

    Huntington's disease mice
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The treatment also improved motor function and extended the survival time of the Huntington's disease mice.
    2 context sentences
    Summary · context
    Huntington's disease mice were treated with an FDA-approved antidiabetic glucagon-like peptide 1 receptor agonist, exendin-4 (Ex-4), to test whether euglycemia could be achieved, whether pancreatic dysfunction could be alleviated, and whether the mice showed any neurological benefit.
    Summary · context
    Additionally, motor performance and life span were quantified and mutant huntingtin (mhtt) aggregates were measured in both the pancreas and brain.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In Huntington's disease mice, exendin‑4 extended survival time.

    In plain wordsIn mice with Huntington's disease, exendin‑4 increased survival time.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseSurvival time
    Study

    mousen: not reported in source

    Huntington's disease mice
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The treatment also improved motor function and extended the survival time of the Huntington's disease mice.
    2 context sentences
    Summary · context
    Huntington's disease mice were treated with an FDA-approved antidiabetic glucagon-like peptide 1 receptor agonist, exendin-4 (Ex-4), to test whether euglycemia could be achieved, whether pancreatic dysfunction could be alleviated, and whether the mice showed any neurological benefit.
    Summary · context
    Additionally, motor performance and life span were quantified and mutant huntingtin (mhtt) aggregates were measured in both the pancreas and brain.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In Huntington's disease mice, improvements during exendin‑4 treatment correlated with reduced mutant huntingtin aggregates in islet cells.

    In plain wordsIn mice with Huntington's disease, improvements during exendin‑4 treatment were linked to fewer mutant huntingtin aggregates in islet cells.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseIslet mutant huntingtin aggregates
    Study

    mousen: not reported in source

    Huntington's disease mice
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    These clinical improvements were correlated with reduced accumulation of mhtt protein aggregates in both islet and brain cells.
    2 context sentences
    Summary · context
    Huntington's disease mice were treated with an FDA-approved antidiabetic glucagon-like peptide 1 receptor agonist, exendin-4 (Ex-4), to test whether euglycemia could be achieved, whether pancreatic dysfunction could be alleviated, and whether the mice showed any neurological benefit.
    Summary · context
    Additionally, motor performance and life span were quantified and mutant huntingtin (mhtt) aggregates were measured in both the pancreas and brain.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In Huntington's disease mice, improvements during exendin‑4 treatment correlated with reduced mutant huntingtin aggregates in brain cells.

    In plain wordsIn mice with Huntington's disease, improvements during exendin‑4 treatment were linked to fewer mutant huntingtin aggregates in brain cells.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBrain mutant huntingtin aggregates
    Study

    mousen: not reported in source

    Huntington's disease mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    These clinical improvements were correlated with reduced accumulation of mhtt protein aggregates in both islet and brain cells.
    2 context sentences
    Summary · context
    Huntington's disease mice were treated with an FDA-approved antidiabetic glucagon-like peptide 1 receptor agonist, exendin-4 (Ex-4), to test whether euglycemia could be achieved, whether pancreatic dysfunction could be alleviated, and whether the mice showed any neurological benefit.
    Summary · context
    Additionally, motor performance and life span were quantified and mutant huntingtin (mhtt) aggregates were measured in both the pancreas and brain.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.